Skip to content
‹ Back to IndustriesHealthcare

As Omicron Variant Spreads, At-Home Tests May Not Be Home for the Holidays

Omicron is the word on everyone’s tongues this holiday season, as the latest COVID-19 variant is surging just as the country enters peak travel dates. Already, airports have seen the most traffic since before the pandemic. The Biden administration has implemented testing requirements, regardless of vaccination status, to all international travelers to help curb the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Omicron is the word on everyone’s tongues this holiday season, as the latest COVID-19 variant is surging just as the country enters peak travel dates. Already, airports have seen the most traffic since before the pandemic. The Biden administration has implemented testing requirements, regardless of vaccination status, to all international travelers to help curb the spread. At-home tests have fast become a popular way for people to check their COVID-status, and the industry is having to adjust quickly as variants develop.

According to Gerald Commissiong, the Chief Executive Officer of Todos Medical, some at-home tests have already been rendered ineffective as the already-existent variants have changed the sequences in the virus.

“We need to start thinking about a completely new set of tests that are able to detect different parts of the virus that do not mutate,” said Commissiong.

Todos Medical is working on their own 3CL protease test that wouldn’t rely on the ever-changing sequence of the virus to detect it.

“That may be a solution to get around a mutating virus,” he said.

Another challenge during the holiday season regarding at-home tests is the delayed delivery times for packages, which could render a test potentially useless if the tested individual later encountered someone with the virus, or if the integrity of the test degraded during the shipping process. He says increasing the number of local labs is a workaround for this situation to help lessen delivery time. Commissiong spoke highly of the vaccines, though stressed that they are designed to prevent hospitalization and death.

“If you get sick, you’re less likely to have a severe disease and potentially less likely to get long COVID,” said Commissiong.

He called this “a call to action,” considering many people who have had the virus have dealt with extended issues tasting, smelling, brain fog and even worse symptoms. Commissiong spoke of the necessity to develop a strategy in how to implement rapid tests. Without such a strategy in place, he recommends the PCR test for the holiday,

“The PCR test is really the best test if you are going to go and see people and are worried you could be carrying the disease,” said Commissiong.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Access TeleCare pharmacist Ashley Selby describes a telehealth antimicrobial stewardship model sized to each hospital's gaps. Joint Commission Standard MM.09.01.01 and 42 CFR 482.42 require a qualified physician and/or pharmacist leader, not a full-time hire, and a 14-study meta-analysis found telehealth stewardship cut antibiotic days of therapy without changing mortality.

  • 01Joint Commission Standard MM.09.01.01, in force since January 2023, requires a physician and/or pharmacist qualified in infectious diseases or stewardship to lead the program, and its committee note allows remote participation.
  • 02The Board of Pharmacy Specialties counts more than 2,380 BCIDP pharmacists nationally, while many small hospitals still assign stewardship to pharmacists without ID training.
  • 03A 14-study meta-analysis found telehealth stewardship raised guideline adherence and cut antibiotic days of therapy, but did not significantly change mortality.

Nov 9, 2026

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512